Veregen® is an ointment used to treat external genital warts. In the USA and Canada, in 15 European countries (Germany, Austria, Switzerland, Spain, the Netherlands, Belgium, Norway, Denmark, Finnland, Sweden, the Czech Republic, Poland, Serbia, Hungary, Slovakia) and Taiwan Veregen® is already marketed by our partners. Sales and marketing partnerships are also in place for this drug in a large number of other countries in Europe, Asia and America. An overview of our partners can be found here. The sales generated with Veregen® are continually rising and making a valuable contribution to financing the Company.
As an innovative drug, Veregen® is based on a defined extract from green tea leaves obtained in a highly complex and specifically developed process
Medigene in-licensed the basic rights to the active ingredient of Veregen® in 1999 and then completed the clinical development of Veregen®. Subsequently, Medigene successfully obtained a marketing authorization by the approval process of the US Food and Drug Administration (FDA). Veregen® is the first, and to date one of a very small number of innovative plant-based drug approved by the FDA. Furthermore, Medigene is the first German biotech company to have a drug on the US market.
Veregen® is currently available in the US, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Norway, Sweden, the Czech Republic, Slovakia, Hungary, Poland, Belgium, Denmark, Finland) as well as in Taiwan and Canada and was approved in further countries.
Veregen® is also listed in recognized treatment guidelines. The US Center for Disease Control and Prevention In its current treatment guidelines for sexually transmitted diseases, recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, the “2012 European Guideline for the Management of Anogenital Warts” includes Sinecatechins 10% & 15% ointment (Veregen®) as a recommended treatment option for genital warts.
The partners anticipate market launches in further countries in 2015. Particularly, the successive launch of Veregen® ointment for the treatment of genital warts in the UK, Ireland, Italy, Portugal, Croatia, Latvia, Lithuania and Estonia is anticipated to start in the second half of 2015.
Veregen® is a trademark of Medigene AG.
Polyphenon E® is a trademark of Mitsui Norin Co., Ltd.